摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氮杂双环[3.3.1]壬烷-5-甲酰氯 | 119103-13-8

中文名称
1-氮杂双环[3.3.1]壬烷-5-甲酰氯
中文别名
——
英文名称
1-Azabicyclo[3.3.1]nonane-5-carbonyl chloride
英文别名
——
1-氮杂双环[3.3.1]壬烷-5-甲酰氯化学式
CAS
119103-13-8
化学式
C9H14ClNO
mdl
MFCD18806589
分子量
187.66
InChiKey
YKAVMHBKJQZFPX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
    申请人:Chu Daniel
    公开号:US20090197863A1
    公开(公告)日:2009-08-06
    A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R 1 , R 2 , R 3 , and R 4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
    具有以下式(I)或式(II)所示结构的化合物: 其中变量Y,R1,R2,R3和R4如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物,以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性改善的疾病、疾病和症状。
  • US8088760B2
    申请人:——
    公开号:US8088760B2
    公开(公告)日:2012-01-03
  • [EN] BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)<br/>[FR] INHIBITEURS À BASE DE COMPOSÉS BENZOXAZOLE-CARBOXAMIDE DE L'ACTIVITÉ POLY(ADP-RIBOSE)POLYMÉRASE (PARP)
    申请人:LEAD THERAPEUTICS INC
    公开号:WO2009099736A2
    公开(公告)日:2009-08-13
    A compound having the structure set forth in Formula (I) or Formula (II): Formula (I) Formula (II) wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
查看更多